Get 40% Off
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks

Bain Capital's $551 million bid sends Estia Health shares to near 5-year high

Published 08/06/2023, 08:57 PM
Updated 08/07/2023, 11:46 AM
© Reuters. FILE PHOTO: Logo of Bain Capital is screened at a news conference in Tokyo, Japan September 28, 2017. REUTERS/Kim Kyung-Hoon

By Rishav Chatterjee and Scott Murdoch

(Reuters) -Global private equity firm Bain Capital will pay A$838 million ($551.3 million) for Australian aged care operator Estia Health, pushing the takeover target's stock to a near five-year high in a sign that appetite for deals down under remains strong.

The Sydney-based Estia said on Monday it had signed a deal to finalise the takeover at A$3.20 per share which is a 25.5% premium to Estia's stock closing price on June 6, before the offer was first disclosed.

Shares of Estia Health were up 9.9% at A$3.12 as of 0045 GMT, their highest since Sept 2018.

The purchase extends Bain Capital's focus on Australia where its prized asset is the Virgin Australia airline it bought during the pandemic, which is currently preparing for a public market listing.

In a statement, Bain Capital said Estia would be added to the firm's $14 billion worth of capital it has deployed in the global healthcare sector.

Estia's stock has seesawed from a peak of $A7 in 2015 to as low as A$1 in March 2020 when Australia began to implement strict pandemic lockdowns.

In June, the company updated the market on its intentions to back Bain Capital's increased offer of $A3 per share to A$3.20. It said it would provide limited access to its books to the suitor in April.

Estia is one of Australia's largest aged care operators, having more than 6,500 places in 70 sites across the country.

"The Board is confident as to the outlook for the business, however, it recognises that the scheme allows shareholders to realise certain cash value now at an attractive premium," Estia Chair Gary Weiss said on Monday.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Estia's board unanimously recommended its shareholders vote in favor of the proposal. A shareholder vote is set to happen in November.

"The problem is now that with the rapid rise in interest rates the buyers that would buy a restructured asset post-Bain Capital are greatly reduced in the market," said Brad Smoling, Smoling Stockbroking managing director.

"If they acquire Estia Health they may be stuck with it in the days ahead."

The company said in a statement that under the deal, it is permitted to pay fully franked dividends of up to A$0.12 per share.

($1 = 1.5200 Australian dollars)

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.